Europe Acute Respiratory Distress Syndrome (ARDS) Market is expected to grow with the CAGR of 9.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-acute-respiratory-distress-syndrome-ards-market

Europe acute respiratory distress syndrome (ARDS) market is a highly consolidated market, which includes more number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the Europe acute respiratory distress syndrome (ARDS) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

• In May 2021, Medtronic launched SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio.

Gilead Sciences Inc. is the dominating player in the Europe acute respiratory distress syndrome (ARDS) market. The other key players existing in the market includes Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS and among others.

Gilead Sciences Inc.

Gilead Sciences Inc. is headquartered in California, U.S. and was founded in the year 1987. The company focuses on discovering and developing therapeutics for people with life-threatening diseases. Some of the product categories of the market include HIV/AIDS, COVID-19, Liver Diseases, Hematology/Oncology, Cardiovascular Inflammation/Respiratory, Other Medicines out of which nflammation/Respiratory is the market focused category.

For instance,

• In July 2020, Gilead Sciences Inc. initiated clinical testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19. This testing helped the company enhance its antiviral product portfolio, thereby strengthening its footprints over the market

The company has wide presence across Europe, Asia-Pacific, North America. In addition, company also generate its revenue from various subsidiaries such as Asegua Therapeutics LLC (U.S.), Forty Seven,Inc.(U.S.), Forty Seven Holdings,LLC.(U.S.), Gilead Alberta, LLC (U.S.), Gilead Apollo, LLC.(U.S.), Gilead Biopharmaceutics US LLC (U.S.).

Terumo Corporation

Terumo Corporation is headquartered in Japan and was founded in 1921. The company focuses on giving large portfolio medical products for clinical practices. Some of the product categories of the market include Terumo Interventional Systems, Neurovascular Division, Cardiovascular Division, Vascular Graft Division out of which Cardiovascular Division is the market focused category.

For instance,

• In April 2020, Terumo Corporation has doubled the extracorporeal membrane oxygenation ECMO Production and Supply. ECMO consists of an oxygenator and centrifugal pump which is used for the patients with severe respiratory failure. This has helped company to increase its market growth in the market

The company has wide presence across EMEA, Greater China, Asia, U.S. In addition, company also generate its revenue from various subsidiaries such as Terumo BCT, Inc.(U.S.), MicroVention, Inc.(U.S.), Terumo Aortic Limited (U.K.), Terumo (Thailand) Co.,Ltd.(Thailand), Terumo Penpol (India).

Getinge AB.

Getinge AB is headquartered in Gothenburg, Sweden and was founded in 1904. The company focuses on providing hospitals and life sciences institutions with various medical products and improve the clinical results. Some of the product categories of the market include Hospital, Life Sciences out of which Extracorporeal Life Support is the market focused category.

For instance,

• In October 2020, Getinge added new features in mechanical ventilation called NAVA- Neurally Adjusted Ventilatory Assist. NAVA can help all types of patients breathe, from tiny premature babies weighing a few hundred grams to frail older patients. This has helped the company to increase its revenue in the market

The company has wide presence across EMEA, U.S, Asia. In addition, company also generate its revenue from various subsidiaries such as Getinge Australia Pty Ltd., (Australia), Getinge Belgium NV. (Belgium), Getinge do Brasil (Brazil), Equipamentos Medicos Ltda Maquet Colombia S.A.S. (Colombia), Getinge France SAS (France).